The estimated Net Worth of Christine Matthews is at least $5.49 ezer dollars as of 6 June 2022. Ms. Matthews owns over 82 units of Zosano Pharma Corp stock worth over $2,342 and over the last 5 years she sold ZSAN stock worth over $3,147. In addition, she makes $0 as Chief Financial Officer és Principal Financial Officer at Zosano Pharma Corp.
Christine has made over 3 trades of the Zosano Pharma Corp stock since 2021, according to the Form 4 filled with the SEC. Most recently she sold 82 units of ZSAN stock worth $58 on 6 June 2022.
The largest trade she's ever made was selling 8,116 units of Zosano Pharma Corp stock on 31 March 2022 worth over $1,704. On average, Christine trades about 1,238 units every 46 days since 2020. As of 6 June 2022 she still owns at least 4,183 units of Zosano Pharma Corp stock.
You can see the complete history of Ms. Matthews stock trades at the bottom of the page.
Christine E. Matthews serves as Chief Financial Officer, Principal Financial Officer of the Company. Christine Matthews has been appointed as Interim Chief Financial Officer of the Company effective 2/1/2020. She has served as the Company’s Vice President, Corporate Controller, since January 2019. From August 2015 to January 2019, Ms. Matthews served as an accounting and financial consultant with Resources Global Professionals (“RGP”). Prior to joining RGP, from September 2013 to June 2015, Ms. Matthews served as Senior Director of Finance at Cepheid, Inc., a biotechnology company. Ms. Matthews received a B.S. in Business Administration with an Emphasis in Accounting from the University of Colorado at Boulder.
Christine Matthews is 51, she's been the Chief Financial Officer és Principal Financial Officer of Zosano Pharma Corp since 2020. There are 6 older and 1 younger executives at Zosano Pharma Corp. The oldest executive at Zosano Pharma Corp is Dr. Donald J. Kellerman, 66, who is the VP of Clinical Devel. & Medical Affairs.
Christine's mailing address filed with the SEC is C/O ZOSANO PHARMA CORPORATION, 34790 ARDENTECH COURT, FREMONT, CA, 94555.
Over the last 10 years, insiders at Zosano Pharma Corp have traded over $5,506,679 worth of Zosano Pharma Corp stock and bought 790,627 units worth $1,835,090 . The most active insiders traders include M James Barrett, Enterprise Associates 12, L... és Steve Elms. On average, Zosano Pharma Corp executives and independent directors trade stock every 60 days with the average trade being worth of $44,258. The most recent stock trade was executed by Christine Matthews on 6 June 2022, trading 82 units of ZSAN stock currently worth $58.
Zosano Pharma Corporation is a clinical-stage biopharmaceutical company focused on developing products where rapid administration of approved molecules with established safety and efficacy profiles may provide substantial benefit to patients, in markets where patients remain underserved by existing therapies. The company's transdermal microneedle system technology consists of titanium microneedles coated with drug that are designed to enable rapid systemic administration of therapeutics to patients. Zosano's lead product candidate is Qtrypta™ (M207), which is a proprietary formulation of zolmitriptan designed to be delivered via its transdermal microneedle system technology, as an acute treatment for migraine.
Zosano Pharma Corp executives and other stock owners filed with the SEC include: